Clinical trials: Antithrombotics
Chronic Subdural Hematoma, Anticoagulant-induced Bleeding
Management of Anticoagulants and Antithrombotics in Patients With CSDH
Primary objective of the study will be to compare, up to 6 months after surgery, number of relapses (post operative re-bleeding) or intracerebral hemorrhage (others than subdural hematomas) and thromboembolic or cardiovascular…
- Conditions
- Chronic Subdural Hematoma, Anticoagulant-induced Bleeding, Thromboembolic Stroke, Cardiovascular Stroke
- Trial name
- THERCA (NCT05079295)
- Testing
- CSDH evacuation
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- University Hospital of Ferrara
Skin Graft Complications
Antithrombotics and Complications in Skin Grafts
Patients who were referred to cutaneous surgery and needed full thickness or split skin grafting and using antitrombotic or non-antitrombotic therapies were observed.
- Trial name
- NCT04231305
- Where
- Denmark
- Volunteers
- 172 people
- Sponsor
- Aalborg University Hospital
Hematologic Neoplasms, Thrombocytopenia
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
Background: Antithrombotic therapy in the context of treatment related thrombocytopenia (i.e. low levels of platelets) is not uncommon.
- Conditions
- Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
- Trial name
- MATTER (NCT03288441)
- Testing
- Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug
- Where
- 21 sites in United States, Israel and 2 more
- Volunteers
- 300 people
- Sponsor
- Maastricht University Medical Center
Antithrombotics Prescriptions
A Prescription Support Tool for Oral Antithrombotic Combinations
From a systematic review of international guidelines (2012-2018), a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital…
- Trial name
- COMBI-AT (NCT03630874)
- Testing
- Evaluate the impact of a prescription support tool
- Volunteers
- 478 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Infarction
Antiplatelet Therapy for Silent Brain Infarction
Silent brain infarction (SBI) or incidental infarct is common. Recent studies revealed individuals with SBI have an increased risk of future stroke.
- Trial name
- ANTISBI (NCT03318744)
- Testing
- Aspirin
- Where
- China
- Volunteers
- 3,400 people
- Sponsor
- First People's Hospital of Shenyang
Heart Valve Disease
Randomized On-X Anticoagulation Trial
Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently…
- Trial name
- PROACT (NCT00291525)
- Testing
- On-X valve using reduced anticoagulation, On-X Valve with Standard warfarin Therapy
- Where
- 49 sites in United States, Canada
- Volunteers
- 977 people
- Sponsor
- On-X Life Technologies, Inc.
Venous Thromboembolism
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors.
- Trial name
- REVNEWANTICO (NCT01210755)
- Testing
- Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Major Haemorrhage
Major Bleeding Risk Associated With Antithrombotics
Prospective, multicenter, observational study with a three-year inclusion period (from January 1, 2012 to December 31, 2015) and a 6-month follow-up
- Trial name
- SACHA (NCT02886533)
- Testing
- Antithrombotic
- Where
- 12 sites in France
- Volunteers
- 6,484 people
- Sponsor
- Rennes University Hospital
Ischemic Stroke, Cerebral Infarction
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
The primary objective of this study is to evaluate whether, in patients with first-ever atherothrombotic or lacunar stroke without any previous history of atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT), the…
- Conditions
- Ischemic Stroke, Cerebral Infarction, Brain Ischemia, Brain Infarction
- Trial name
- SAFFO (NCT02684825)
- Testing
- Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring
- Where
- Italy
- Volunteers
- 317 people
- Sponsor
- Danilo Toni
Myocardial Infarction
APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Reocclusion of the infarct artery is observed in about 30% of patients within three months after successful thrombolysis for acute myocardial infarction (MI).
- Trial name
- NCT00138034
- Testing
- Percutaneous coronary intervention (PCI)
- Where
- Netherlands
- Volunteers
- 49 people
- Sponsor
- Heartcenter, University Medical Center St. Radboud
Antithrombotics, Colonoscopy
Patients on Antithrombotics for Colonoscopy
The use of antithrombotics (antiplatelet agents and anticoagulants) is increasing with an aging global population.Management of antithrombotics in patients undergoing invasive procedures including gastrointestinal endoscopy…
- Trial name
- NCT03363061
- Where
- Hong Kong
- Volunteers
- 6,000 people
- Sponsor
- Chinese University of Hong Kong
Cardiovascular Diseases
Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling
The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) in hospitalized patients.
- Trial name
- OptimAT (NCT03477331)
- Where
- Switzerland
- Volunteers
- 444 people
- Sponsor
- University Hospital, Geneva
Stroke
Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated with Antithrombotics for an Ischemic Stroke.
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
- Trial name
- QUATRO (NCT05741593)
- Testing
- Analysis of the verbatim from the transcription of the recorded interviews.
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Stroke of Basilar Artery, Optical Coherence Tomography
Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation
Evidence regarding the role of early (<24 hours) antithrombotics post-revascularization with either intravenous thrombolysis (IVT), endovascular thrombectomy (EVT), or a combination of both remains scarce.
- Conditions
- Stroke of Basilar Artery, Optical Coherence Tomography, Antithrombotics, Endovascular Thrombectomy
- Trial name
- NCT04121611
- Testing
- Unfractionated heparin, Acetylsalicylic Acid (ASA)
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Sunnybrook Health Sciences Centre
Atrial Fibrillation, Coronary Artery Disease
The Greek AntiPlatElet Atrial Fibrillation Registry.
Approximately 5% to 7% of patients undergoing percutaneous coronary intervention for the treatment of coronary artery disease, require chronic oral anticoagulation on top of aspirin and a P2Y12 receptor antagonist, mainly due to…
- Trial name
- GRAPE-AF (NCT03362788)
- Testing
- VKA, NOAC
- Where
- Greece
- Volunteers
- 654 people
- Sponsor
- Attikon Hospital
Atrial Fibrillation, Venous Thromboembolism
START-Register: Survey on Anticoagulated Patients Register
This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs).
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- NCT02219984
- Testing
- Anticoagulants
- Where
- Italy
- Volunteers
- 15,410 people
- Sponsor
- GUALTIERO PALARETI
COVID-19 Pneumonia, Thrombosis
Practice Variation on Antithrombotics in COVID-19
Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations.
- Conditions
- COVID-19 Pneumonia, Thrombosis, COVID-19 Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Trial name
- NCT04998799
- Testing
- Current clinical practices of participating physicians
- Where
- India
- Volunteers
- 435 people
- Sponsor
- NMC Specialty Hospital